Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Puma Stock Jumps as Biotech Gets Good News From the FDA | Barron's
PBYI Stock Nosedives | Puma Biotechnology's Nerlynx Revenue Falls
Home │ NERLYNX® (neratinib) tablets
puma biotechnology earnings Off 66% - canerofset.com
Buy Nerlynx (neratinib) Online • Price & Costs | TheSocialMedwork
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib) | PharmaShots
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Nerlynx Labeling Updated to Include Data on Antidiarrheal Prophylaxis - MPR
Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology
Puma biotech and Specialised Therapeutics signs agreement to commercialize NERLYNX®
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Rx Item-Nerlynx 40Mg (48.31) Mg Tab 180 By Puma Biotech
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
Puma Biotechnology Files NDS for Nerlynx in Canada | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017
